11 Jun 2017
Professor Patrick Gunning discusses his work developing small molecule inhibitors for STAT proteins, with the aim of developing new cancer treatments. STAT-3 is found to be hyperactive in over 70% of human cancer, leading to uncontrolled cell growth, whilst STAT-5 has recently been identified as a target in haematological oncology.
This video won the Drug Discovery & Development Video Interview of the Year in the 2018 Scientists' Choice Awards. Find out more about the awards here
University of Toronto Mississauga
Patrick Gunning is full professor and Canada Research Chair in Medicinal Chemistry at University of Toronto. In 2007, Patrick accepted an Assistant Professorship position at the University of Toronto Mississauga Chemistry Department. In the last eight years he has developed a dynamic and diverse medicinal chemistry program targeting protein-protein interactions, a most challenging of targets. Moreover, Patrick’s team develop inhibitors of proteins that drive the most rare and lethal of human cancers, including glioblastoma, acute myeloid leukemia, multiple myeloma, and refractory medullablastoma.